Abbott Receives FDA Emergency Use Authorization for Four-Virus Respiratory Test

Abbott Laboratories has secured Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new diagnostic test capable of simultaneously detecting four common respiratory viruses from a single sample. The Alinity m Resp-4-Plex test identifies SARS-CoV-2 (the virus that causes COVID-19), Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) using one nasal or nasopharyngeal swab.

The development aims to streamline the testing process for both patients and healthcare providers. By consolidating four separate tests into one, the new assay reduces the number of swabs needed, potentially lessening patient discomfort and decreasing the time spent in healthcare settings. This efficiency also extends to laboratory operations, requiring fewer resources and less manual processing.

Simultaneous testing is crucial given the overlapping symptoms of these respiratory illnesses, which can make clinical diagnosis challenging. The Alinity m Resp-4-Plex utilizes Polymerase Chain Reaction (PCR) technology, known for its high sensitivity, and operates on Abbott's Alinity m system. This platform is designed for flexibility, allowing for random access testing that can expedite result delivery.

Abbott indicates that the test is intended to help manage the burden on healthcare systems, particularly during peak respiratory illness seasons. The assay is designated for use in clinical laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 to perform moderate or high-complexity tests in the United States.

By providing rapid and comprehensive results, the test is expected to aid healthcare professionals in making timely treatment decisions and implementing appropriate infection control measures to prevent further spread.